Plasmepsin V FRET Substrate

<strong>Plasmepsin V FRET Substrate </strong>_x000D_ <strong>Catalog number:</strong> B2011254_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 1751.1 g/mol_x000D_ <strong>Supplied as:</strong> Lyophilized_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20 °C_x000D_ <strong>Keywords:</strong> PMV substrate_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Šnebergerová P, Bartošová-Sojková P, Jalovecká M, Sojka D. Plasmepsin-like Aspartyl Proteases in Babesia Pathogens. 2021 Sep 26;10(10):1241._x000D_ 2: Brancucci NMB, Heussler VT, Grüring C. Targeting Plasmodium Plasmepsin V: Hitting Two Birds with One Stone Trends Parasitol. 2020 Feb;36(2):85-87._x000D_ 3: Barber J, Sikakana P, Sadler C, Baud D, Valentin JP, Roberts R. A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria Toxicol Res (Camb). 2021 Feb 15;10(2):203-213._x000D_ 4: Favuzza P, de Lera Ruiz M, Thompson JK, Triglia T, Ngo A, Steel RWJ, Vavrek M, Christensen J, Healer J, Boyce C, Guo Z, Hu M, Khan T, Murgolo N, Zhao L, Penington JS, Reaksudsan K, Jarman K, Dietrich MH, Richardson L, Guo KY, Lopaticki S, Tham WH, Rottmann M, Papenfuss T, Robbins JA, Boddey JA, Sleebs BE, Sabroux HJ, McCauley JA, Olsen DB, Cowman AF. Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle Cell Host Microbe. 2020 Apr 8;27(4):642-658.e12._x000D_ 5: Inoue J, Silva M, Fofana B, Sanogo K, Mårtensson A, Sagara I, Björkman A, Veiga MI, Ferreira PE, Djimde A, Gil JP. Plasmodium falciparum Plasmepsin 2 Duplications, West Africa Emerg Infect Dis. 2018 Aug;24(8):1591-3._x000D_ 6: Kinena L, Leitis G, Kanepe-Lapsa I, Bobrovs R, Jaudzems K, Ozola V, Suna E, Jirgensons A. Azole-based non-peptidomimetic plasmepsin inhibitors Arch Pharm (Weinheim). 2018 Sep;351(9):e1800151._x000D_ 7: Cheuka PM, Dziwornu G, Okombo J, Chibale K. Plasmepsin Inhibitors in Antimalarial Drug Discovery: Medicinal Chemistry and Target Validation (2000 to Present) J Med Chem. 2020 May 14;63(9):4445-4467._x000D_ 8: Zogota R, Kinena L, Withers-Martinez C, Blackman MJ, Bobrovs R, Pantelejevs T, Kanepe-Lapsa I, Ozola V, Jaudzems K, Suna E, Jirgensons A. Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D Eur J Med Chem. 2019 Feb 1;163:344-352._x000D_ 9: Meissner KA, Kronenberger T, Maltarollo VG, Trossini GHG, Wrenger C. Targeting the Plasmodium falciparum plasmepsin V by ligand-based virtual screening Chem Biol Drug Des. 2019 Mar;93(3):300-312._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/30580023">10: Loesbanluechai D, Kotanan N, de Cozar C, Kochakarn T, Ansbro MR, Chotivanich K, White NJ, Wilairat P, Lee MCS, Gamo FJ, Sanz LM, Chookajorn T, Kümpornsin K. Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine Int J Parasitol Drugs Drug Resist. 2019 Apr;9:16-22. </a>_x000D_ _x000D_ <strong>Products Related to Plasmepsin V FRET Substrate can be found at</strong> <a href="https://moleculardepot.com/product-category/Substrates/"> Substrates</a>